相关实验视频

Updated: Jul 16, 2025

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

2岁至12岁以下遗传性血管患者的兰德鲁马布:第三期春季研究的结果

Marcus Maurer¹, William R Lumry², H Henry Li³

¹Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

The journal of allergy and clinical immunology. In practice

|September 20, 2023

概括

兰德鲁马布显著减少了遗传性血管 (HAE) 发作,并改善了2至12岁儿童的生活质量. 治疗表明,发作率下降了94.8%,大多数患者仍然没有发作.

科学领域:

免疫学免疫学免疫学
儿科儿科儿科
药理学药理学是指药理学的学科.

背景情况:

遗传性血管 (HAE) 的症状通常在童年开始,严重的发作会影响生活质量.
对于6岁以下的儿童,没有批准长期预防治疗.

研究的目的:

评估2岁至12岁以下患者的兰阿德鲁马布的安全性,药理动力学和疗效.
评估拉纳德卢马布对儿科HAE患者与健康相关的生活质量 (HRQoL) 的影响.

主要方法:

春季研究招募了21名患有HAE的儿科患者.
2-6岁的患者每4周服用150毫克兰阿德鲁马布 (Q4W);6-12岁的患者每2周服用150毫克兰阿德鲁马布 (Q2W),如果在26周内没有发作,可以选择切换到Q4W.
治疗持续时间为52周.

主要成果:

没有报告任何严重的治疗出现的不良事件 (TEAE) 或因TEAE而中止治疗.
从基线观察到HAE攻击率减少了94.8% (1.84到0.08次/月).
21名患者中有16名 (76.2%) 没有发作,HRQoL有显著改善.

结论:

拉纳德鲁马布 (150毫克Q2W和Q4W) 是安全有效的,用于预防2至12岁儿童的HAE发作.
治疗lanadelumab导致在这个儿科群体的健康相关的生活质量大幅改善.

关键词:

与健康相关的生活质量.遗传性血管腺遗传性血管腺遗传性血管腺拉纳德鲁马巴巴是什么意思长期预防长期预防儿科儿科儿科药理动力学上的作用.药理动力学药理动力学

更多相关视频

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...